Notably, the study was not powered to evaluate risk of stent thrombosis or systemic In aggregate, the data to date on compari- sons of double versus triple therapy demonstrate that double therapy significantly reduces the risk of bleeding without a signal of harm with re- gard to stent thrombosis in clinical trials that en- rolled both patients with stable ischemic disease and patients with ACS. With regard to the anti- thrombotic dosages studied, only the RE-DUAL PCI trial and WOEST trials studied antithrombotic dosages known to reduce the risk of systemic CLINICAL STATEMENTS AND GUIDELINES The ongoing AU- GUSTUS (A Study of Apixaban in Patients With Atrial Fibrillation, not Caused by a Heart Valve Problem, who are at Risk for Thrombosis due to Having had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart) trial is an open-label 2 2 factorial RCT to evaluate the safety of apixaban versus vi- tamin K antagonist and aspirin versus aspirin pla- cebo in patients with AF and ACS or PCI.S7.4-24 The ENTRUST-AF-PCI (Edoxaban Treatment Versus Vi- tamin K Antagonist in Patients With Atrial Fibril- lation Undergoing Percutaneous Coronary Inter- vention) is an ongoing trial evaluating edoxaban treatment versus vitamin K antagonist treatment in patients with AF undergoing PCI.S7.4-25 These trials will provide further evidence on treatment approaches designed to mitigate bleeding while reducing the risks of stent thrombosis and sys- temic thromboembolism. 8. The ISAR-TRIPLE (Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent was a randomized, open- label trial of patients receiving anticoagulation who underwent PCI with drug-eluting stents. Patients received concomitant anticoagulant and aspirin and were randomized to 6 weeks versus 6 months of clopidogrel. 